Erratum: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability (PLoS Pathogens (2016) 12:4 (e1005537) DOI: 10.1371/journal.ppat.1005537);Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Mason, Rosemarie D ^a   Welles, Hugh C ^a   Adams, Cameron ^a   Chakrabarti, Bimal K ^b   Gorman, Jason ^a   Zhou, Tongqing ^a   Nguyen, Richard ^a   O’Dell, Sijy ^a   Lusvarghi, Sabrina ^c   Bewley, Carole A ^c   Li, Hui ^d   Shaw, George M ^d   Sheng, Zizhang ^e   Shapiro, Lawrence ^e   Wyatt, Richard ^f   Kwong, Peter D ^a   Mascola, John R ^a   Roederer, Mario ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; VIRUS ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY ISOLATION; ARTICLE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; SERODIAGNOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES; EPITOPES; GENE PRODUCTS, ENV; HIV ANTIBODIES; HUMANS; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84964896857     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005674     Document Type: Erratum

References (115)

1. Mascola JR, Haynes BF, HIV-1 neutralizing antibodies: understanding nature's pathways. Immunological reviews. 2013;254(1):225–44. Epub 2013/06/19. doi: 10.1111/imr.1207523772623; PubMed Central PMCID: PMC3738265.
2. Haynes BF, McElrath MJ, Progress in HIV-1 vaccine development. Current opinion in HIV and AIDS. 2013;8(4):326–32. Epub 2013/06/08. 23743722; PubMed Central PMCID: PMC3947525.
3. Overbaugh J, Morris L, The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012;2(1):a007039. doi: 10.1101/cshperspect.a00703922315717; PubMed Central PMCID: PMC3253031.
4. Burton DR, Mascola JR, Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16(6):571–6. doi: 10.1038/ni.315825988889.
5. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. Epub 2010/07/10. doi: 10.1126/science.118765920616233; PubMed Central PMCID: PMC2965066.
6. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–7. Epub 2011/07/19. doi: 10.1126/science.120722721764753; PubMed Central PMCID: PMC3351836.
7. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469–76. Epub 2013/04/05. doi: 10.1038/nature1205323552890; PubMed Central PMCID: PMC3637846.
8. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–7. Epub 2010/07/10. doi: 10.1126/science.119281920616231; PubMed Central PMCID: PMC2981354.
9. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–9. Epub 2009/09/05. doi: 10.1126/science.117874619729618; PubMed Central PMCID: PMC3335270.
10. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011;85(19):9998–10009. Epub 2011/07/29. doi: 10.1128/JVI.05045-1121795340; PubMed Central PMCID: PMC3196428.
11. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–U117. doi: 10.1038/Nature10373 WOS:000295080500041. 21849977
12. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55–62. doi: 10.1038/nature1303624590074.
13. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–12. Epub 2012/11/16. doi: 10.1038/nature1154423151583.
14. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011;6(9):e23532. Epub 2011/10/08. doi: 10.1371/journal.pone.002353221980336; PubMed Central PMCID: PMC3184076.
15. Zhu Z, Qin HR, Chen W, Zhao Q, Shen X, Schutte R, et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol. 2011;85(21):11401–8. Epub 2011/09/02. doi: 10.1128/JVI.05312-1121880764; PubMed Central PMCID: PMC3194990.
16. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515(7525):138–42. doi: 10.1038/nature1360125186731; PubMed Central PMCID: PMC4224615.
17. Scharf L, Scheid JF, Lee JH, West AP, Jr.Chen C, Gao H, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014;7(3):785–95. doi: 10.1016/j.celrep.2014.04.00124767986; PubMed Central PMCID: PMC4109818.
18. Kwong PD, Mascola JR, Nabel GJ, Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13(9):693–701. Epub 2013/08/24. doi: 10.1038/nri351623969737.
19. Girard MP, Picot V, Longuet C, Nabel GJ, Report of the 2014 Cent Gardes HIV Vaccine Conference—Part 1: Neutralizing Antibodies; Fondation Merieux Conference Center, Veyrier du Lac, France, 5–7 October 2014. Vaccine. 2015. 25769208.
20. Wibmer CK, Moore PL, Morris L, HIV broadly neutralizing antibody targets. Current opinion in HIV and AIDS. 2015;10(3):135–43. 25760932; PubMed Central PMCID: PMC4437463.
21. Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, et al. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses. 1998;14(14):1271–80. Epub 1998/10/09. 9764911.
22. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol. 2011;85(14):7029–36. Epub 2011/05/06. doi: 10.1128/JVI.00171-1121543485; PubMed Central PMCID: PMC3126567.
23. Robinson HL, Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther. 2013;13(2):197–207. Epub 2012/11/08. doi: 10.1517/14712598.2012.74352723130709.
24. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science translational medicine. 2014;6(228):228ra39. Epub 2014/03/22. doi: 10.1126/scitranslmed.300773024648342; PubMed Central PMCID: PMC4116665.
25. Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013;9(1):e1003106. Epub 2013/01/10. doi: 10.1371/journal.ppat.100310623300456; PubMed Central PMCID: PMC3536657.
26. McGuire AT, Glenn JA, Lippy A, Stamatatos L, Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol. 2014;88(5):2645–57. Epub 2013/12/20. doi: 10.1128/JVI.03228-1324352455; PubMed Central PMCID: PMC3958080.
27. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L, Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7(1):e1001251. Epub 2011/01/21. doi: 10.1371/journal.ppat.100125121249232; PubMed Central PMCID: PMC3020924.
28. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011;85(10):4828–40. Epub 2011/03/11. doi: 10.1128/JVI.00198-1121389135; PubMed Central PMCID: PMC3126191.
29. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118–22. doi: 10.1038/nature1160423103874; PubMed Central PMCID: PMC3809838.
30. Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol. 2013;87(9):4882–94. Epub 2013/02/15. doi: 10.1128/JVI.03424-1223408621; PubMed Central PMCID: PMC3624332.
31. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9):e1003618. Epub 2013/09/27. doi: 10.1371/journal.ppat.100361824068931; PubMed Central PMCID: PMC3777863.
32. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A. 2013;110(45):18256–61. Epub 2013/10/23. doi: 10.1073/pnas.131435111024145402; PubMed Central PMCID: PMC3831437.
33. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A. 2011;108(27):11181–6. Epub 2011/06/22. doi: 10.1073/pnas.110301210821690411; PubMed Central PMCID: PMC3131343.
34. Dugast AS, Chan Y, Hoffner M, Licht A, Nkolola J, Li H, et al. Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies. PLoS One. 2014;9(5):e97229. Epub 2014/05/14. doi: 10.1371/journal.pone.009722924820481; PubMed Central PMCID: PMC4018276.
35. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science translational medicine. 2011;3(81):81ra36. Epub 2011/05/06. doi: 10.1126/scitranslmed.300235121543722; PubMed Central PMCID: PMC3718279.
36. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89–93. doi: 10.1038/nature1076622217938; PubMed Central PMCID: PMC3271177.
37. Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, et al. HIV-1 vaccines. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–4.
38. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505(7484):502–8. Epub 2013/12/20. doi: 10.1038/nature1289324352234; PubMed Central PMCID: PMC3946913.
39. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol. 2012;86(2):947–60. doi: 10.1128/JVI.06155-1122031948; PubMed Central PMCID: PMC3255805.
40. de Silva TI, Aasa-Chapman M, Cotten M, Hue S, Robinson J, Bibollet-Ruche F, et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol. 2012;86(2):930–46. doi: 10.1128/JVI.06126-1122072758; PubMed Central PMCID: PMCPMC3255814.
41. Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjornsson J, et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol. 2012;86(2):961–71. doi: 10.1128/JVI.06315-1122072782; PubMed Central PMCID: PMCPMC3255861.
42. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, et al. Proof of principle for epitope-focused vaccine design. Nature. 2014;507(7491):201–6. Epub 2014/02/07. doi: 10.1038/nature1296624499818.
43. Brocca-Cofano E, McKinnon K, Demberg T, Venzon D, Hidajat R, Xiao P, et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine. 2011;29(17):3310–9. Epub 2011/03/09. doi: 10.1016/j.vaccine.2011.02.06621382487; PubMed Central PMCID: PMC3079049.
44. Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, et al. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Retrovirology. 2012;9:56. Epub 2012/07/18. doi: 10.1186/1742-4690-9-5622799593; PubMed Central PMCID: PMC3418562.
45. Bogers WM, Davis D, Baak I, Kan E, Hofman S, Sun Y, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 2008;382(2):217–25. Epub 2008/10/25. doi: 10.1016/j.virol.2008.09.01618947849; PubMed Central PMCID: PMC2723753.
46. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A. 2007;104(44):17477–82. Epub 2007/10/25. doi: 10.1073/pnas.070739910417956985; PubMed Central PMCID: PMC2077281.
47. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J, Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. Journal of acquired immune deficiency syndromes. 1992;5(7):639–46. 1613662.
48. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207–10. Epub 2000/02/02. doi: 10.1038/7231810655111.
49. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155(3):531–9. Epub 2013/11/19. doi: 10.1016/j.cell.2013.09.06124243013; PubMed Central PMCID: PMC3846288.
50. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–8. doi: 10.1038/nature1274424172905; PubMed Central PMCID: PMC4017780.
51. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5(5):e1000433. Epub 2009/05/14. doi: 10.1371/journal.ppat.100043319436712; PubMed Central PMCID: PMC2674935.
52. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010;16(10):1117–9. Epub 2010/10/05. doi: 10.1038/nm.223320890292; PubMed Central PMCID: PMC2952052.
53. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277–80. Epub 2013/11/01. doi: 10.1038/nature1274624172896.
54. Tsibris AM, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, et al. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One. 2011;6(12):e28047. Epub 2011/12/14. doi: 10.1371/journal.pone.002804722164225; PubMed Central PMCID: PMC3229503.
55. Pal R, Galmin L, Pereira LE, Li B, Zhang J, Li D, et al. Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. Virology. 2012;432(1):173–83. Epub 2012/07/10. 22769870.
56. Bixby JG, Laur O, Johnson WE, Desrosiers RC, Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res Hum Retroviruses. 2010;26(10):1115–31. Epub 2010/09/15. doi: 10.1089/aid.2010.002920836705; PubMed Central PMCID: PMC2982722.
57. Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc Natl Acad Sci U S A. 2015;112(34):10780–5. doi: 10.1073/pnas.150973111226261312; PubMed Central PMCID: PMC4553804.
58. Song K, Bolton DL, Wei CJ, Wilson RL, Camp JV, Bao S, et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci U S A. 2010;107(51):22213–8. Epub 2010/12/08. doi: 10.1073/pnas.101553610821135247; PubMed Central PMCID: PMC3009829.
59. Fazi B, Cope MJ, Douangamath A, Ferracuti S, Schirwitz K, Zucconi A, et al. Unusual binding properties of the SH3 domain of the yeast actin-binding protein Abp1: structural and functional analysis. J Biol Chem. 2002;277(7):5290–8. doi: 10.1074/jbc.M10984820011668184.
60. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480(7377):336–43. doi: 10.1038/nature1069622113616; PubMed Central PMCID: PMC3406929.
61. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J, Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol. 2002;76(9):4634–42. 11932429; PubMed Central PMCID: PMCPMC155086.
62. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol. 2005;79(14):8828–34. doi: 10.1128/JVI.79.14.8828-8834.200515994776; PubMed Central PMCID: PMCPMC1168733.
63. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A. 2012;109(15):5663–8. doi: 10.1073/pnas.111239110922451932; PubMed Central PMCID: PMC3326499.
64. Mori T, Gustafson KR, Pannell LK, Shoemaker RH, Wu L, McMahon JB, et al. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein expression and purification. 1998;12(2):151–8. doi: 10.1006/prep.1997.08389518455.
65. Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schon A, et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A. 2004;101(14):5036–41. Epub 2004/03/31. doi: 10.1073/pnas.030795310115051887; PubMed Central PMCID: PMC387369.
66. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, et al. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009;5(4):e1000360. doi: 10.1371/journal.ppat.100036019343205; PubMed Central PMCID: PMC2655723.
67. Bewley CA, Otero-Quintero S, The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. Journal of the American Chemical Society. 2001;123(17):3892–902. Epub 2001/07/18. 11457139.
68. Donaldson MM, Kao SF, Eslamizar L, Gee C, Koopman G, Lifton M, et al. Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. Journal of immunological methods. 2012;386(1–2):10–21. Epub 2012/09/08. doi: 10.1016/j.jim.2012.08.01122955212; PubMed Central PMCID: PMC3646372.
69. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D, Koup RA, et al. Amine-reactive dyes for dead cell discrimination in fixed samples. Current protocols in cytometry / editorial board, J Paul Robinson, managing editor [et al]. 2010; Chapter 9:Unit 9 34. Epub 2010/06/26. doi: 10.1002/0471142956.cy0934s5320578108; PubMed Central PMCID: PMC2915540.
70. Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, et al. Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature communications. 2015;6:6565. doi: 10.1038/ncomms756525858157.
71. Brochet X, Lefranc MP, Giudicelli V, IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36(Web Server issue):W503–8. doi: 10.1093/nar/gkn31618503082; PubMed Central PMCID: PMC2447746.
72. Giudicelli V, Brochet X, Lefranc MP, IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc. 2011;2011(6):695–715. doi: 10.1101/pdb.prot563321632778.
73. Garlick RL, Kirschner RJ, Eckenrode FM, Tarpley WG, Tomich CS, Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. AIDS Res Hum Retroviruses. 1990;6(4):465–79. 2187501.
74. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79(16):10108–25. Epub 2005/07/30. doi: 10.1128/JVI.79.16.10108-10125.200516051804; PubMed Central PMCID: PMC1182643.
75. Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol. 2011;85(12):5764–72. doi: 10.1128/JVI.00342-1121490100; PubMed Central PMCID: PMC3126289.
76. Fairman J, Moore J, Lemieux M, Van Rompay K, Geng Y, Warner J, et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin. 2009;5(3):141–50. 18690014; PubMed Central PMCID: PMC2728146.
77. Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, Buzby AP, et al. Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol. 2009;83(6):2686–96. doi: 10.1128/JVI.02237-0819129440; PubMed Central PMCID: PMC2648285.
78. Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, et al. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. J Virol. 2015;89(16):8130–51. doi: 10.1128/JVI.01221-1426018167; PubMed Central PMCID: PMC4524250.
79. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273–89. doi: 10.1084/jem.2009037819487424; PubMed Central PMCID: PMCPMC2715054.
80. Fischer W, Apetrei C, Santiago ML, Li Y, Gautam R, Pandrea I, et al. Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol. 2012;86(24):13217–31. doi: 10.1128/JVI.01862-1223055550; PubMed Central PMCID: PMCPMC3503124.
81. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439–52. doi: 10.1128/JVI.02108-0919939925; PubMed Central PMCID: PMC2812321.
82. Lopker M, Easlick J, Sterrett S, Decker JM, Barbian H, Learn G, et al. Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol. 2013;87(10):5477–92. doi: 10.1128/JVI.03419-1223468494; PubMed Central PMCID: PMC3648171.
83. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial agents and chemotherapy. 1997;41(7):1521–30. Epub 1997/07/01. 9210678; PubMed Central PMCID: PMC163952.
84. Esser MT, Mori T, Mondor I, Sattentau QJ, Dey B, Berger EA, et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol. 1999;73(5):4360–71. Epub 1999/04/10. 10196334; PubMed Central PMCID: PMC104217.
85. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–86. Epub 2012/04/06. doi: 10.1056/NEJMoa111342522475592; PubMed Central PMCID: PMC3371689.
86. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1):126–38. doi: 10.1016/j.cell.2013.03.01823540694; PubMed Central PMCID: PMC3792590.
87. Yu L, Guan Y, Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. Front Immunol. 2014;5:250. doi: 10.3389/fimmu.2014.0025024917864; PubMed Central PMCID: PMC4040451.
88. Kwong PD, Mascola JR, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37(3):412–25. Epub 2012/09/25. doi: 10.1016/j.immuni.2012.08.01222999947.
89. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458(7238):636–40. Epub 2009/03/17. doi: 10.1038/nature0793019287373.
90. Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, Scott JK, Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One. 2011;6(3):e16857. doi: 10.1371/journal.pone.001685721479208; PubMed Central PMCID: PMCPMC3068138.
91. Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat Commun. 2015;6:6565. doi: 10.1038/ncomms756525858157; PubMed Central PMCID: PMC4403371.
92. Palker TJ, Muir AJ, Spragion DE, Staats HF, Langlois A, Montefiori DC, The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology. 1996;224(2):415–26. doi: 10.1006/viro.1996.05488874502.
93. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC, Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol. 2001;75(8):3903–15. doi: 10.1128/JVI.75.8.3903-3915.200111264379; PubMed Central PMCID: PMCPMC114881.
94. Kent KA, Gritz L, Stallard G, Cranage MP, Collignon C, Thiriart C, et al. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS. 1991;5(7):829–36. 1716442.
95. Edinger AL, Ahuja M, Sung T, Baxter KC, Haggarty B, Doms RW, et al. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J Virol. 2000;74(17):7922–35. 10933700; PubMed Central PMCID: PMCPMC112323.
96. Kent KA, Rud E, Corcoran T, Powell C, Thiriart C, Collignon C, et al. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses. 1992;8(6):1147–51. 1380261.
97. Choi WS, Collignon C, Thiriart C, Burns DP, Stott EJ, Kent KA, et al. Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. J Virol. 1994;68(9):5395–402. 7520089; PubMed Central PMCID: PMCPMC236939.
98. Babas T, Le Grand R, Dormont D, Bahraoui E, Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS Res Hum Retroviruses. 1997;13(13):1109–19. 9282816.
99. Robinson JE, Cole KS, Elliott DH, Lam H, Amedee AM, Means R, et al. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res Hum Retroviruses. 1998;14(14):1253–62. 9764909.
100. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, et al. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol. 2003;77(18):9993–10003. 12941910; PubMed Central PMCID: PMCPMC224602.
101. Cole KS, Alvarez M, Elliott DH, Lam H, Martin E, Chau T, et al. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology. 2001;290(1):59–73. 11883006.
102. Kuwata T, Katsumata Y, Takaki K, Miura T, Igarashi T, Isolation of potent neutralizing monoclonal antibodies from an SIV-Infected rhesus macaque by phage display. AIDS Res Hum Retroviruses. 2011;27(5):487–500. doi: 10.1089/aid.2010.019120854170.
103. Kent KA, Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein. Journal of medical primatology. 1995;24(3):145–9. Epub 1995/05/01. 8751054.
104. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–70. doi: 10.1038/nature1037321849977; PubMed Central PMCID: PMC3393110.
105. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011;85(19):9998–10009. doi: 10.1128/JVI.05045-1121795340; PubMed Central PMCID: PMC3196428.
106. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40(5):669–80. doi: 10.1016/j.immuni.2014.04.00824768348; PubMed Central PMCID: PMC4057017.
107. Bohl C, Bowder D, Thompson J, Abrahamyan L, Gonzalez-Ramirez S, Mao Y, et al. A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. PLoS One. 2013;8(7):e69406. doi: 10.1371/journal.pone.006940623936006; PubMed Central PMCID: PMCPMC3720275.
108. Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, et al. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. J Virol. 2012;86(13):7052–9. doi: 10.1128/JVI.00107-1222532675; PubMed Central PMCID: PMCPMC3416332.
109. Yeh WW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri A, et al. Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. J Virol. 2010;84(12):6018–32. doi: 10.1128/JVI.02741-0920357097; PubMed Central PMCID: PMCPMC2876635.
110. Pancera M, Wyatt R, Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology. 2005;332(1):145–56. doi: 10.1016/j.virol.2004.10.04215661147.
111. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A. 2014;111(7):E738–47. doi: 10.1073/pnas.131951211124550318; PubMed Central PMCID: PMCPMC3932900.
112. Doores KJ, Burton DR, Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol. 2010;84(20):10510–21. doi: 10.1128/JVI.00552-1020686044; PubMed Central PMCID: PMC2950566.
113. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, et al. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol. 2011;85(16):8217–26. doi: 10.1128/JVI.00756-1121653673; PubMed Central PMCID: PMCPMC3147955.
114. Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011;85(17):8954–67. doi: 10.1128/JVI.00754-1121715490; PubMed Central PMCID: PMCPMC3165784.
115. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR, Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol. 2009;83(21):10892–907. doi: 10.1128/JVI.01142-0919692465; PubMed Central PMCID: PMCPMC2772753.